NasdaqGS - Nasdaq Real Time Price USD

Krystal Biotech, Inc. (KRYS)

155.68

-3.37

(-2.12%)

At close: April 25 at 4:00 PM EDT

Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Krystal Biotech (KRYS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 2 days ago

KRYS
-2.12%
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707, a modified HSV-1 vector designed to deliver genes encoding both human interleukin-12 (IL-12) and interleukin-2 (IL-2) to the lung, for the treatment of patients with

GlobeNewswire 3 days ago

KRYS
-2.12%
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks 8 days ago

KRYS
-2.12%
Recent 3.8% pullback isn't enough to hurt long-term Krystal Biotech (NASDAQ:KRYS) shareholders, they're still up 437% over 5 years

Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...

Simply Wall St. 10 days ago

KRYS
-2.12%
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical modelPITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 (IL-

GlobeNewswire 21 days ago

KRYS
-2.12%
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks 24 days ago

KRYS
-2.12%
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them. These three strong buy biotech stocks are joining the upper ranks of their industry with promising new drugs and encouraging financials that justify serious consideration. Given the timeline of clinical trials and new rele

InvestorPlace 29 days ago

AXSM

KRYS
-2.12%
CPRX
Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks last month

KRYS
-2.12%
Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?

Krystal Biotech, Inc. (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks last month

KRYS
-2.12%
^GSPC
What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock

Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

KRYS
-2.12%
Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks last month

KRYS
-2.12%
Chief Accounting Officer Kathryn Romano Sells 5,000 Shares of Krystal Biotech Inc (KRYS)

Kathryn Romano, the Chief Accounting Officer of Krystal Biotech Inc (NASDAQ:KRYS), has sold 5,000 shares of the company on February 28, 2024, according to a recent SEC filing.

GuruFocus.com last month

KRYS
-2.12%
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years

It will take a lot, but this goal isn't out of reach for these stocks.

Motley Fool last month

VKTX

KRYS
-2.12%
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call Transcript

Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call Transcript February 26, 2024 Krystal Biotech, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by and welcome to the Krystal Biotech Fourth Quarter and Full Year 2023 […]

Insider Monkey last month

KRYS
-2.12%
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 44th Annual Health Care Conference, which takes place in Boston on March 4-6. Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at 9:50 am ET during the conference and host investor meetings on March 5. A webcast of the presentation will be availabl

GlobeNewswire last month

KRYS
-2.12%
Here's Why Momentum in Krystal Biotech, Inc. (KRYS) Should Keep going

Krystal Biotech, Inc. (KRYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks last month

KRYS
-2.12%
Q4 2023 Krystal Biotech Inc Earnings Call

Q4 2023 Krystal Biotech Inc Earnings Call

Thomson Reuters StreetEvents last month

KRYS
-2.12%
Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates

Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of 157.69% and 119.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

KRYS
-2.12%
Krystal Biotech Inc (KRYS) Reports Strong Q4 and Full Year 2023 Financial Results

Commercial Launch of VYJUVEK Drives Revenue Growth Amidst Pipeline Advancements

GuruFocus.com last month

KRYS
-2.12%
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

• Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of the use of B-VEC eyedrop formulation • Reached alignment with FDA to enable approval of B-VEC eyedrop formulation for the treatment of lesions in the eye of DEB patients • First patient dosed in Phase 1 KB408 trial for the treatment of AATD; five active clinical trials in 2024 • Strong balance sheet, closing the year with $594.1M in cash and investments PITTSBURGH, Feb. 26, 2024 (GLOBE

GlobeNewswire last month

KRYS
-2.12%

Performance Overview

Return	KRYS	S&P 500
YTD	+25.49%	+5.84%
1-Year	+83.15%	+22.03%
3-Year	+98.14%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Krystal Biotech, Inc. (KRYS)

Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable

Recent 3.8% pullback isn't enough to hurt long-term Krystal Biotech (NASDAQ:KRYS) shareholders, they're still up 437% over 5 years

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why

Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?

What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock

Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?

Chief Accounting Officer Kathryn Romano Sells 5,000 Shares of Krystal Biotech Inc (KRYS)

2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years

Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call Transcript

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Here's Why Momentum in Krystal Biotech, Inc. (KRYS) Should Keep going

Q4 2023 Krystal Biotech Inc Earnings Call

Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates

Krystal Biotech Inc (KRYS) Reports Strong Q4 and Full Year 2023 Financial Results

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Performance Overview